Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
BENGALURU, India, Feb. 9, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, ...
Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe
BENGALURU, India, Dec. 1, 2023 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris' biosimilars business in 31 European countries has been successfully completed. Following the acquisition of ...
Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North America Ahead of Schedule
BRIDGEWATER, N.J. and BENGALURU, India, Sept. 6, 2023 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the Company has completed the integration of the acquired biosimilars business from Viatris inNorth America (United St...
